Filing Details
- Accession Number:
- 0000904454-13-001088
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-10-03 18:59:12
- Reporting Period:
- 2013-10-01
- Filing Date:
- 2013-10-03
- Accepted Time:
- 2013-10-03 18:59:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1488039 | Atossa Genetics Inc | ATOS | Surgical & Medical Instruments & Apparatus (3841) | 264753208 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1008227 | C Steven Quay | 4105 E. Madison Street, Suite 320 Seattle WA 98112 | Ceo | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2013-10-01 | 7,265 | $5.66 | 4,268,315 | No | 4 | S | Indirect | By Ensisheim Partners, LLC |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Ensisheim Partners, LLC |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 584,543 | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a trading plan previously adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The trading plan was previously reviewed and approved by the Company's board of directors in accordance with Rule 10b5-1.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.57 to $5.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- Ensisheim Partners, LLC is wholly owned by the Reporting Person and Dr. Shu-Chih Chen, the Chief Scientific Officer of the Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of all such securities for purposes of Section 16 or any other purpose.
Billionaire Hedge Funds
